Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
Elodie Lauret Marie JosephAmos KirilovskyBenoît LecoesterCarine El SissyLaura BoullerotLaurie RanganAmélie MarguierFlorent TochetMagalie DossetJihane BoustaniPatrice RavelRomain BoidotLaurie SpehnerNacilla Haicheur-AdjouriFlorence MarliotJean-René PallandreFrancis BonnefoyViorel ScripcariuMarc Van den EyndeEmmanuel CornillotCéline MirjoletFranck PagesOlivier AdotéviPublished in: Journal for immunotherapy of cancer (2022)
Our results highlight the ability of CRT to stimulate strong antitumor T-cell-mediated immunity and tissue resident memory T activation in TME, to foster immune checkpoint inhibitors action. These findings have implications in clinic for the design clinical trials combining chemoradiation with immunotherapy.
Keyphrases
- clinical trial
- immune response
- rectal cancer
- locally advanced
- working memory
- patient safety
- quality improvement
- primary care
- squamous cell carcinoma
- emergency medicine
- randomized controlled trial
- radiation therapy
- dendritic cells
- heart failure
- cell therapy
- mesenchymal stem cells
- bone marrow
- replacement therapy
- study protocol